Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283217587> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W4283217587 endingPage "1051" @default.
- W4283217587 startingPage "1049" @default.
- W4283217587 abstract "Intravenous immunoglobulin (IVIg) contains pooled immunoglobulins from the plasma of healthy blood donors. All plasma samples are tested for HIV, hepatitis viruses (A, B, and C), and parvovirus B19. As part of this screening step, nucleic acid amplification technology (NAT) is used and allows the presence of specific antibodies targeting viral structures that are commonly used to test for infection status, such as anti-hepatitis B surface antigen (HBs) or anti-hepatitis B virus core (HBc) antibodies. For this reason, manufacturers point to the possibility of false-positive viral serological test results following IVIg treatment due to the passive transfer of antibodies. IVIg therapy is commonly used to manage patients with severe, treatment-refractory autoimmune skin diseases. The aim of this cohort study was to retrospectively quantify newly-discovered positive serological HBV test results after IVIg treatment in patients with autoimmune skin diseases. Between March 2018 and June 2021, 28 patients with autoimmune skin diseases received IVIg therapy, of whom 17 were longitudinally followed-up. None of the patients had evidence of active HBV infection prior to IVIg therapy. All patients (n = 17) had detectable anti-HBs antibodies and 12 patients had anti-HBc antibodies 4 weeks after commencing IVIg treatment. Passive antibody transfer seems the most likely interpretation. Nevertheless, complete serological hepatitis assessment should be performed to exclude a new infection. We recommend hepatitis screening before IVIg therapy to prevent diagnostic confusion which may arise due to passive antibody transfer." @default.
- W4283217587 created "2022-06-22" @default.
- W4283217587 creator A5000503244 @default.
- W4283217587 creator A5004458225 @default.
- W4283217587 creator A5011018551 @default.
- W4283217587 creator A5021559096 @default.
- W4283217587 creator A5055267795 @default.
- W4283217587 creator A5065751866 @default.
- W4283217587 creator A5087513808 @default.
- W4283217587 creator A5090549024 @default.
- W4283217587 date "2022-06-21" @default.
- W4283217587 modified "2023-10-14" @default.
- W4283217587 title "Challenge of hepatitis B testing following intravenous immunoglobulin therapy in patients with autoimmune skin diseases" @default.
- W4283217587 cites W2005837517 @default.
- W4283217587 cites W2017312408 @default.
- W4283217587 cites W2028768606 @default.
- W4283217587 cites W2050163016 @default.
- W4283217587 cites W2085466356 @default.
- W4283217587 cites W2791839818 @default.
- W4283217587 cites W2895705155 @default.
- W4283217587 cites W2951855787 @default.
- W4283217587 cites W3008885123 @default.
- W4283217587 cites W3011215093 @default.
- W4283217587 cites W3015024578 @default.
- W4283217587 cites W3080818382 @default.
- W4283217587 cites W3137328381 @default.
- W4283217587 doi "https://doi.org/10.1111/1346-8138.16500" @default.
- W4283217587 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35726741" @default.
- W4283217587 hasPublicationYear "2022" @default.
- W4283217587 type Work @default.
- W4283217587 citedByCount "2" @default.
- W4283217587 countsByYear W42832175872023 @default.
- W4283217587 crossrefType "journal-article" @default.
- W4283217587 hasAuthorship W4283217587A5000503244 @default.
- W4283217587 hasAuthorship W4283217587A5004458225 @default.
- W4283217587 hasAuthorship W4283217587A5011018551 @default.
- W4283217587 hasAuthorship W4283217587A5021559096 @default.
- W4283217587 hasAuthorship W4283217587A5055267795 @default.
- W4283217587 hasAuthorship W4283217587A5065751866 @default.
- W4283217587 hasAuthorship W4283217587A5087513808 @default.
- W4283217587 hasAuthorship W4283217587A5090549024 @default.
- W4283217587 hasBestOaLocation W42832175871 @default.
- W4283217587 hasConcept C159654299 @default.
- W4283217587 hasConcept C203014093 @default.
- W4283217587 hasConcept C2522874641 @default.
- W4283217587 hasConcept C2776029263 @default.
- W4283217587 hasConcept C2777203481 @default.
- W4283217587 hasConcept C2777382497 @default.
- W4283217587 hasConcept C2780593183 @default.
- W4283217587 hasConcept C2909916134 @default.
- W4283217587 hasConcept C45189115 @default.
- W4283217587 hasConcept C71924100 @default.
- W4283217587 hasConceptScore W4283217587C159654299 @default.
- W4283217587 hasConceptScore W4283217587C203014093 @default.
- W4283217587 hasConceptScore W4283217587C2522874641 @default.
- W4283217587 hasConceptScore W4283217587C2776029263 @default.
- W4283217587 hasConceptScore W4283217587C2777203481 @default.
- W4283217587 hasConceptScore W4283217587C2777382497 @default.
- W4283217587 hasConceptScore W4283217587C2780593183 @default.
- W4283217587 hasConceptScore W4283217587C2909916134 @default.
- W4283217587 hasConceptScore W4283217587C45189115 @default.
- W4283217587 hasConceptScore W4283217587C71924100 @default.
- W4283217587 hasFunder F4320320879 @default.
- W4283217587 hasIssue "10" @default.
- W4283217587 hasLocation W42832175871 @default.
- W4283217587 hasLocation W42832175872 @default.
- W4283217587 hasOpenAccess W4283217587 @default.
- W4283217587 hasPrimaryLocation W42832175871 @default.
- W4283217587 hasRelatedWork W1984475196 @default.
- W4283217587 hasRelatedWork W2028125236 @default.
- W4283217587 hasRelatedWork W2131541658 @default.
- W4283217587 hasRelatedWork W2159602954 @default.
- W4283217587 hasRelatedWork W2160193513 @default.
- W4283217587 hasRelatedWork W2373048719 @default.
- W4283217587 hasRelatedWork W2377681251 @default.
- W4283217587 hasRelatedWork W3136868089 @default.
- W4283217587 hasRelatedWork W3201360696 @default.
- W4283217587 hasRelatedWork W4301209712 @default.
- W4283217587 hasVolume "49" @default.
- W4283217587 isParatext "false" @default.
- W4283217587 isRetracted "false" @default.
- W4283217587 workType "article" @default.